Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F. Valtorta E, et al. Among authors: ercolani c. Int J Cancer. 2013 Sep 1;133(5):1259-65. doi: 10.1002/ijc.28106. Epub 2013 Mar 16. Int J Cancer. 2013. PMID: 23404247 Free article.
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: ercolani c. Clin Cancer Res. 2011 Apr 1;17(7):2055-64. doi: 10.1158/1078-0432.CCR-10-1920. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307144
Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.
Lattanzio R, Marchisio M, La Sorda R, Tinari N, Falasca M, Alberti S, Miscia S, Ercolani C, Di Benedetto A, Perracchio L, Melucci E, Iacobelli S, Mottolese M, Natali PG, Piantelli M; CINBO (Consorzio Interuniversitario Nazionale per Bio-Oncologia). Lattanzio R, et al. Among authors: ercolani c. Int J Cancer. 2013 Mar 1;132(5):1022-31. doi: 10.1002/ijc.27751. Epub 2012 Sep 1. Int J Cancer. 2013. PMID: 22847294
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: ercolani c. Expert Opin Pharmacother. 2013 Apr;14(6):699-706. doi: 10.1517/14656566.2013.779672. Epub 2013 Mar 9. Expert Opin Pharmacother. 2013. PMID: 23472669
Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres.
Melucci E, Cosimelli M, Carpanese L, Pizzi G, Izzo F, Fiore F, Golfieri R, Giampalma E, Sperduti I, Ercolani C, Sciuto R, Mancini R, Garufi C, Diodoro MG, Mottolese M; Italian Society of Locoregional Therapies in Oncology (S.I.T.I.L.O.). Melucci E, et al. Among authors: ercolani c. J Exp Clin Cancer Res. 2013 Mar 6;32(1):13. doi: 10.1186/1756-9966-32-13. J Exp Clin Cancer Res. 2013. PMID: 23497522 Free PMC article. Clinical Trial.
miR-155 drives telomere fragility in human breast cancer by targeting TRF1.
Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeftner S. Dinami R, et al. Among authors: ercolani c. Cancer Res. 2014 Aug 1;74(15):4145-56. doi: 10.1158/0008-5472.CAN-13-2038. Epub 2014 May 29. Cancer Res. 2014. PMID: 24876105
Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.
Sapino A, Maletta F, Verdun di Cantogno L, Macrì L, Botta C, Gugliotta P, Scalzo MS, Annaratone L, Balmativola D, Pietribiasi F, Bernardi P, Arisio R, Viberti L, Guzzetti S, Orlassino R, Ercolani C, Mottolese M, Viale G, Marchiò C. Sapino A, et al. Among authors: ercolani c. Oncologist. 2014 Nov;19(11):1118-26. doi: 10.1634/theoncologist.2014-0195. Epub 2014 Oct 16. Oncologist. 2014. PMID: 25323485 Free PMC article.
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F, Botti C, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: ercolani c. J Exp Clin Cancer Res. 2016 Apr 2;35:62. doi: 10.1186/s13046-016-0338-7. J Exp Clin Cancer Res. 2016. PMID: 27039292 Free PMC article.
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
Barba M, Vici P, Pizzuti L, Di Lauro L, Sergi D, Di Benedetto A, Ercolani C, Sperati F, Terrenato I, Botti C, Mentuccia L, Iezzi L, Gamucci T, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Saccà M. Barba M, et al. Among authors: ercolani c. BMC Cancer. 2017 Feb 6;17(1):101. doi: 10.1186/s12885-016-3045-z. BMC Cancer. 2017. PMID: 28166748 Free PMC article.
93 results